Cargando…
TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our pr...
Autores principales: | Nai, Yaru, Du, Li, Shen, Meiying, Li, Tingting, Huang, Jingjing, Han, Xiaojian, Luo, Feiyang, Wang, Wang, Pang, Da, Jin, Aishun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721281/ https://www.ncbi.nlm.nih.gov/pubmed/34988114 http://dx.doi.org/10.3389/fmolb.2021.756599 |
Ejemplares similares
-
IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities
por: Du, Li, et al.
Publicado: (2021) -
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
por: Snajdauf, Martin, et al.
Publicado: (2021) -
GeneTrail: A Framework for the Analysis of High-Throughput Profiles
por: Gerstner, Nico, et al.
Publicado: (2021) -
TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex
por: Simoes Eugénio, Mélanie, et al.
Publicado: (2021) -
Unlocking the potential of Tregs: innovations in CAR technology
por: Requejo Cier, Christopher J., et al.
Publicado: (2023)